Atossa Therapeutics, Inc.
(ATOS)
Add Watchlist
1.57 USD -0.01
Closed: 17 May, 3:55 pm
Symbol ATOS
Market Cap 197.4M
Price 1.57
Open 1.60
52-wk High 2.31
50 Day Avg 1.59
Earnings Announcement 2024-08-12
Website https://www.atossatherapeutics.com
Name Atossa Therapeutics, Inc.
Shares Outstanding 125,757,000
Change % -2.4845%
Low 1.55
52-wk Low 0.62
200 Day Avg 1.01
Last Dividend 0.00
Exchange NASDAQ
Volume 805,576
Previous Close 1.61
High 1.60
EPS -0.24
PE -6.54
Avg Volume 1,924,572
CUSIP 04962H506
Atossa Therapeutics, Inc. Outlook
Description Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Currency USD
ISIN US04962H5063
Industry Biotechnology
Changes -0.04
CUSIP 04962H506
Range 0.62 - 2.31
Beta 1.28
CIK 0001488039

Atossa Therapeutics, Inc. News

17-May-2024 6:15 AM

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024

With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.

15-May-2024 9:42 AM

Atossa Therapeutics gives final dose in breast cancer prevention study

Atossa Therapeutics Inc (NASDAQ:ATOS) has given the last patient's final dose in its Karisma-Endoxifen clinical trial, aimed at reducing the chances of breast cancer. Some 240 people took part in the phase two trial, which began in November, Atossa Therapeutics said on Wednesday.

15-May-2024 9:42 AM

Atossa Therapeutics gives final dose in breast cancer prevention study

Atossa Therapeutics Inc (NASDAQ:ATOS) has given the last patient's final dose in its Karisma-Endoxifen clinical trial, aimed at reducing the chances of breast cancer. Some 240 people took part in the phase two trial, which began in November, Atossa Therapeutics said on Wednesday.

15-May-2024 8:30 AM

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

13-May-2024 10:33 AM

Atossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1

Atossa Therapeutics Inc (NASDAQ:ATOS) continued to advance the development of its lead clinical asset (Z)-endoxifen to prevent and treat breast cancer in the first quarter of 2024, exiting the quarter in a strong cash position with no debt. “The first quarter of 2024 was a period of significant progress for our company,” Dr Steven Quay, CEO of the clinical-stage biopharmaceutical company said in a statement.

13-May-2024 10:33 AM

Atossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1

Atossa Therapeutics Inc (NASDAQ:ATOS) continued to advance the development of its lead clinical asset (Z)-endoxifen to prevent and treat breast cancer in the first quarter of 2024, exiting the quarter in a strong cash position with no debt. “The first quarter of 2024 was a period of significant progress for our company,” Dr Steven Quay, CEO of the clinical-stage biopharmaceutical company said in a statement.

13-May-2024 8:50 AM

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer

09-May-2024 7:57 PM

Shhh! 3 Secret Penny Stocks Flying Below Wall Street's Radar

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

07-May-2024 9:29 AM

Atossa Therapeutics welcomes updated breast cancer screening guidelines

Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that the change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.

07-May-2024 9:29 AM

Atossa Therapeutics welcomes updated breast cancer screening guidelines

Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that the change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.

07-May-2024 8:30 AM

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.